2-4-3--5--tetrahydroxystilbene and Brain-Neoplasms

2-4-3--5--tetrahydroxystilbene has been researched along with Brain-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 2-4-3--5--tetrahydroxystilbene and Brain-Neoplasms

ArticleYear
(-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer.
    Nutrients, 2020, Jun-11, Volume: 12, Issue:6

    Lung cancer (LC) represents the topmost mortality-causing cancer in the U.S. LC patients have overall poor survival rate with limited available treatment options. Dysregulation of the mesenchymal epithelial transition factor (c-MET) and cyclooxygenase 2 (COX2) initiates aggressive LC profile in a subset of patients. The Mediterranean extra-virgin olive oil (EVOO)-rich diet already documented to reduce multiple malignancies incidence. (-)-Oleocanthal (OC) is a naturally occurring phenolic secoiridoid exclusively occurring in EVOO and showed documented anti-breast and other cancer activities via targeting c-MET. This study shows the novel ability of OC to suppress LC progression and metastasis through dual targeting of c-MET and COX-2. Western blot analysis and COX enzymatic assay showed significant reduction in the total and activated c-MET levels and inhibition of COX1/2 activity in the lung adenocarcinoma cells A549 and NCI-H322M, in vitro. In addition, OC treatment caused a dose-dependent inhibition of the HGF-induced LC cells migration. Daily oral treatment with 10 mg/kg OC for 8 weeks significantly suppressed the LC A549-Luc progression and prevented metastasis to brain and other organs in a nude mouse tail vein injection model. Further, microarray data of OC-treated lung tumors showed a distinct gene signature that confirmed the dual targeting of c-MET and COX2. Thus, the EVOO-based OC is an effective lead with translational potential for use as a prospective nutraceutical to control LC progression and metastasis.

    Topics: Adenocarcinoma; Aldehydes; Animals; Brain Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Cyclopentane Monoterpenes; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice, Nude; Olive Oil; Phenols; Phytotherapy; Proto-Oncogene Proteins c-met

2020
(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cells.
    PloS one, 2019, Volume: 14, Issue:8

    (-)-Oleocanthal (oleocanthal) is a phenolic compound found in varying concentrations in extra virgin olive oil oleocanthal has been shown to be active physiologically, benefiting several diseased states by conferring anti-inflammatory and neuroprotective benefits. Recently, we and other groups have demonstrated its specific and selective toxicity toward cancer cells; however, the mechanism leading to cancer cell death is still disputed. The current study demonstrates that oleocanthal, as well as naturally oleocanthal-rich extra virgin olive oils, induced damage to cancer cells' lysosomes leading to cellular toxicity in vitro and in vivo. Lysosomal membrane permeabilization following oleocanthal treatment in various cell lines was assayed via three complementary methods. Additionally, we found oleocanthal treatment reduced tumor burden and extended lifespan of mice engineered to develop pancreatic neuroendocrine tumors. Finally, following-up on numerous correlative studies demonstrating consumption of olive oil reduces cancer incidence and morbidity, we observed that extra virgin olive oils naturally rich in oleocanthal sharply reduced cancer cell viability and induced lysosomal membrane permeabilization while oleocanthal-poor oils did not. Our results are especially encouraging since tumor cells often have larger and more numerous lysosomes, making them especially vulnerable to lysosomotropic agents such as oleocanthal.

    Topics: Aldehydes; Animals; Apoptosis; Brain Neoplasms; Cell Membrane Permeability; Cyclopentane Monoterpenes; Lysosomes; Mice; Necrosis; Neuroectodermal Tumors, Primitive; Olive Oil; Phenols; Plant Oils; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019